SYN Synthetic Biologics, Inc. Commo

0.51
+0  (6%)
Previous Close 0.48
Open 0.50
Price To book 14.63
Market Cap 60.30M
Shares 117,541,000
Volume 2,781,759
Short Ratio 17.04
Av. Daily Volume 624,584

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 2 trial commenced October 2015. 12 week data met endpoints. Phase 2b/3 trial planned for 2017.
SYN-010
Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Pending. Partner Meda has received the go-ahead from the FDA to conduct a Phase 2 proof of concept trial
Flupirtine
Fibromyalgia
License terminated following lack of efficacy shown February 2016
Trimesta
Relapsing-remitting MS in women
Phase 2b topline data released January 5, 2017. Primary endpoint met. Phase 3 trial to be initiated 1H 2018.
SYN-004
C. difficile Infection

Latest News

  1. Synthetic Biologics to Present at the 29th Annual ROTH Conference
  2. Synthetic Biologics reports 4Q loss
  3. Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results
  4. Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017
  5. Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference
  6. Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA
  7. Synthetic Biologics C. Difficile Drug Trial Succeeds
  8. Synthetic Biologics' C. difficile mid-stage study meets main goal
  9. Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
  10. Synthetic Biologics to Present at the Biotech Showcase™ 2017 Conference
  11. Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
  12. Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences
  13. Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants
  14. Nokia, Teva Plunge into Tuesday’s 52-Week Low Club
  15. Synthetic Biologics Prices Secondary Offering
  16. Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants
  17. Synthetic Biologics Announces Commencement of Public Offering of Common Stock and Warrants
  18. ETF’s with exposure to Synthetic Biologics, Inc. : November 1, 2016
  19. Synthetic Biologics Reports Third Quarter 2016 Operational Highlights and Financial Results